DrugPatentWatch Database Preview
Details for Patent: 7,838,032
Email this page to a colleague
Summary for Patent: 7,838,032
| Title: | Sustained release of guaifenesin |
| Abstract: | The invention relates to a novel pharmaceutical sustained release formulation of guaifenesin. The formulation may comprise a hydrophilic polymer, preferably a hydroxypropyl methylcellulose, and a water-insoluble polymer, preferably an acrylic resin, in a ratio range of about one-to-one (1:1) to about nine-to-one (9:1), more preferably a range of about three-to-two (3:2) to about six-to-one (6:1), and most preferably in a range of about two-to-one (2:1) to about four-to-one (4:1) by weight. This formulation capable of providing therapeutically effective bioavailability of guaifenesin for at least twelve hours after dosing in a human subject. The invention also relates to a modified release product which has two portions: a first portion having an immediate release formulation of guaifenesin and a second portion having a sustained release formulation of guaifenesin. The modified release product has a maximum guaifenesin serum concentration equivalent to that of an immediate release guaifenesin tablet, and is capable of providing therapeutically effective bioavailability of guaifenesin for at least twelve hours after dosing in a human subject. |
| Inventor(s): | Davis; Robert D. (Arlington, TX), Blume; Ralph W. (Fort Worth, TX), Keyser; Donald Jeffrey (Southlake, TX) |
| Assignee: | Reckitt Benckiser Inc. (Parsippany, NJ) |
| Application Number: | 10/406,557 |
| Patent Litigation and PTAB cases: | See patent lawsuits and PTAB cases for patent 7,838,032 |
|
Patent Claim Types: see list of patent claims | Compound; Dosage form; |
Drugs Protected by US Patent 7,838,032
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Patented / Exclusive Use | Submissiondate |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Patented / Exclusive Use | >Submissiondate |
International Family Members for US Patent 7,838,032
| Country | Patent Number | Estimated Expiration | Supplementary Protection Certificate | SPC Country | SPC Expiration |
|---|---|---|---|---|---|
| Austria | 391494 | ⤷ Free Forever Trial | |||
| Australia | 2001255680 | ⤷ Free Forever Trial | |||
| Australia | 2003237807 | ⤷ Free Forever Trial | |||
| Australia | 5568001 | ⤷ Free Forever Trial | |||
| Canada | 2405031 | ⤷ Free Forever Trial | |||
| >Country | >Patent Number | >Estimated Expiration | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration |
